St Georges phase III renal carcinoma Pages on BioPortfolio:

BioPortfolio - find a neoplasm
Recent Search Terms used to find this page: neoplasm kidney | kidney neoplasm | histotripsy kidney | neoplasms videos | St Georges phase III renal carcinoma ...
http://www.bioportfolio.com/search/find_a_neoplasm.html...

Biotechnology News Search
(APPA: News ) announced positive results from its pivotal Phase 3 study comparing ...... an investigational anti-angiogenesis drug for renal cell
carcinoma, ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=ne...

York Pharma - Preliminary Results for the Year Ended 30 September 2005
York Pharma recently announced collaboration with St George’s Hospital Medical ... cell in a variety of cancers including melanoma and renal cell carcinoma.
...
http://www.bioportfolio.com/biotech_news/York_Pharma_2.htm...

Carcinoma - 0497009323 - ICON Health Publications
BioPortfolio - St Georges phase III renal carcinoma Targeted therapy for renal cell carcinoma: a new treatment paradigm ... Randomized phase III trial of ...
http://www.bioportfolio.com/bookshop/search/Carcinoma/...

Results from other life science and pharmaceutical sites:

Targeted therapy for renal cell carcinoma: a new treatment paradigm
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, .... Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=19...

(kidney neoplasms[majr] NOT wilms tumor[majr]) AND english[la] AND ...
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. ...
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubme...

Targeted therapy for metastatic renal cell carcinoma
Malignant renal cell carcinoma (RCC) accounts for 2-3% of cancer incidence and ..... Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, ...
http://www.nature.com/bjc/journal/v94/n5/full/6602978a.html...

A brief symptom index for advanced renal cell carcinoma
We conducted secondary data analyses on patient-reported outcomes of 209 metastatic renal cell carcinoma patients participating in a Phase III clinical
...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=15...

Targeted therapy for renal cell carcinoma: a new treatment paradigm
Randomized phase III trial of sorafenib in advanced renal. cell carcinoma (RCC): impact of crossover on survival. In 2006 ASCO. Annual Meeting Proceedings. ...
http://www.baylorhealth.edu/proceedings/20_3/20_3_hutson.pdf...

Biomarkers of Angiogenesis for the Development of Antiangiogenic ...
(2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. ... renal-cell carcinoma. N Engl J Med 356: 115-124; George DJ et al. ...
http://www.medscape.com/viewarticle/576019_References...

Kidney International - Management of advanced renal cancer
Hereditary papillary renal carcinoma (HPRC) is a rare inherited ..... These encouraging results have prompted a phase III study of sorafenib versus placebo
...
http://www.nature.com/ki/journal/v67/n5/full/4495284a.html...

Antitumor activity and biomarker analysis of sunit...[J Clin Oncol ...
2006]; Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. [Lancet. ...
http://www.ncbi.nlm.nih.gov/pubmed/18669461...

Reply: Evaluating the activity of temsirolimus in neuroendocrine ...
Both trials led to further phase III evaluations due to the promising ... Lastly , O'Donnell et al draw analogies between renal cell carcinoma and NEC. ...
http://www.nature.com/bjc/journal/v96/n1/full/6603514a.html...

Targeted therapy of renal cell cancer
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR,. 34. Redman BG, Margolin KA, ... renal cell carcinoma: A randomised, double-blind phase III ...
http://www.biomedcentral.com/content/pdf/cd-910540.pdf...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.